Abstract：With the increase in the rescue success rate of critically ill preterm infants and extremely preterm infants, the incidence rate of bronchopulmonary dysplasia (BPD) is increasing year by year. BPD has a high mortality rate and high possibility of sequelae, which greatly affects the quality of life of preterm infants and brings a heavy burden to their families, and so the treatment of BPD is of vital importance. At present, no consensus has been reached on the treatment measures for BPD. However, recent studies have shown that early application of caffeine can prevent BPD. With reference to the latest studies on the effect of caffeine in the prevention of BPD, this article reviews the mechanism of action of caffeine in reducing pulmonary inflammation, improving morphological abnormalities of lung injury, reducing oxidative stress injury, and improving pulmonary function.
Islam JY, Keller RL, Aschner JL, et al. Understanding the short-and long-term respiratory outcomes of prematurity and bronchopulmonary dysplasia[J]. Am J Respir Crit Care Med, 2015, 192(2):134-156.
[2]
Gibson AM, Doyle LW. Respiratory outcomes for the tiniest or most immature infants[J]. Semin Fetal Neonatal Med, 2014, 19(2):105-111.
Ogawa R, Mori R, Sako M, et al. Drug treatment for bronchopulmonary dysplasia in Japan:questionnaire survey[J]. Pediatr Int, 2015, 57(1):189-192.
[5]
Jarreau PH, Zana-Taïeb E, Maillard A. Bronchopulmonary dysplasia in the newborn:physiopathology, treatment and prevention[J]. Arch Pediatr, 2015, 22(5 Suppl 1):103-104.
[6]
Laube M, Amann E, Uhlig U, et al. Inflammatory mediators in tracheal aspirates of preterm infants participating in a randomized trial of inhaled nitric oxide[J]. PLoS One, 2017, 12(1):e0169352.
[7]
Venkataraman R, Kamaluddeen M, Hasan SU, et al. Intratracheal administration of budesonide-surfactant in prevention of bronchopulmonary dysplasia in very low birth weight infants:a systematic review and meta-analysis[J]. Pediatr Pulmonol, 2017, 52(7):968-975.
[8]
Mueller M, Kramer BW. Stem cells and bronchopulmonary dysplasia-the fve questions:Which cells, when, in which dose, to which patients via which route?[J]. Paediatr Respir Rev, 2017, 24:54-59.
[9]
Yao L, Shi Y, Zhao X, et al. Vitamin D attenuates hyperoxiainduced lung injury through downregulation of Toll-like receptor 4[J]. Int J Mol Med, 2017, 39(6):1403-1408.
[10]
Nair V, Loganathan P, Soraisham AS. Azithromycin and other macrolides for prevention of bronchopulmonary dysplasia:a systematic review and meta-analysis[J]. Neonatology, 2014, 106(4):337-347.
[11]
Spiegler J, Preuß M, Gebauer C, et al. Does breastmilk influence the development of bronchopulmonary dysplasia?[J]. J Pediatr, 2016, 169:76-80.e4.
[12]
Lapcharoensap W, Kan P, Powers RJ, et al. The relationship of nosocomial infection reduction to changes in neonatal intensive care unit rates of bronchopulmonary dysplasia[J]. J Pediatr, 2017, 180:105-109.e1.
Nagasato A, Nakamura M, Kamimura H. Comparative study of the effcacy and safety of caffeine and aminophylline for the treatment of apnea in preterm infants[J]. Yakugaku Zasshi, 2018, 138(2):237-242.
[15]
Taha D, Kirkby S, Nawab U, et al. Early caffeine therapy for prevention of bronchopulmonary dysplasia in preterm infants[J]. J Matern Fetal Neonatal Med, 2014, 27(16):1698-1702.
[16]
Lodha A, Seshia M, McMillan DD, et al. Association of early caffeine administration and neonatal outcomes in very preterm neonates[J]. JAMA Pediatr, 2015, 169(1):33-38.
[17]
Park HW, Lim G, Chung SH, et al. Early caffeine use in very low birth weight infants and neonateal outcomes:a systematic review and Meta-analysis[J]. J Korean Med Sci, 2015, 30(12):1828-1835.
[18]
Niedermaier S, Hilgendorff A. Bronchopulmonary dysplasia-an overview about pathophysiologic concepts[J]. Mol Cell Pediatr, 2015, 2(1):2.
[19]
Cox AM, Gao Y, Perl AT, et al. Cumulative effects of neonatal hyperoxia on murine alveolar structure and function[J]. Pediatr Pulmonol, 2017, 52(5):616-624.
Schneibel KR, Fitzpatrick AM, Ping XD, et al. Inflammatory mediator patterns in tracheal aspirate and their association with bronchopulmonary dysplasia in very low birth weight neonates[J]. J Perinatol, 2013, 33(5):383-387.
[22]
Kumar VH, Lakshminrusimha S, Kishkurno S, et al. Neonatal hyperoxia increases airway reactivity and inflammation in adult mice[J]. Pediatr Pulmonol, 2016, 51(11):1131-1141.
[23]
D'Angio CT, Ambalavanan N, Carlo WA, et al. Blood cytokine profles associated with distinct patterns of bronchopulmonary dysplasia among extremely low birth weight infants[J]. J Pediatr, 2016, 174:45-51.e5.
[24]
Schneibel KR, Fitzpatrick AM, Ping XD, et al. Inflammatory mediator patterns in tracheal aspirate and their association with bronchopulmonary dysplasia in very low birth weight neonates[J]. J Perinatol, 2013, 33(5):383-387.
[25]
Balany J, Bhandari V. Understanding the impact of infection, inflammation, and their persistence in the pathogenesis of bronchopulmonary dysplasia[J]. Front Med (Lausanne), 2015, 2:90.
[26]
Weichelt U, Cay R, Schmitz T, et al. Prevention of hyperoxiamediated pulmonary inflammation in neonatal rats by caffeine[J]. Eur Respir J, 2013, 41(4):966-973.
[27]
Nagatomo T, Jiménez J, Richter J, et al. Caffeine prevents hyperoxia-induced functional and structural lung damage in preterm rabbits[J]. Neonatology, 2016, 109(4):274-281.
[28]
Chou WC, Kao MC, Yue CT, et al. Caffeine mitigates lung inflammation induced by ischemia-reperfusion of lower limbs in rats[J]. Mediators Inflamm, 2015, 2015:361638.
[29]
Oñatibia-Astibia A, Martínez-Pinilla E, Franco R. The potential of methylxanthine-based therapies in pediatric respiratory tract diseases[J]. Respir Med, 2016, 112:1-9.
[30]
Chavez-Valdez R, Ahlawat R, Wills-Karp M, et al. Mechanisms of modulation of cytokine release by human cord blood monocytes exposed to high concentrations of caffeine[J]. Pediatr Res, 2016, 80(1):101-109.
[31]
Köroğlu OA, MacFarlane PM, Balan KV, et al. AntiInflammatory effect of caffeine is associated with improved lung function after lipopolysaccharide-induced amnionitis[J]. Neonatology, 2014, 106(3):235-240.
[32]
Fehrholz M, Speer CP, Kunzmann S. Caffeine and rolipram affect Smad signalling and TGF-β1 stimulated CTGF and transgelin expression in lung epithelial cells[J]. PLoS One, 2014, 9(5):e97357.
[33]
Rath P, Nardiello C, Surate Solaligue DE, et al. Caffeine administration modulates TGF-β signaling but does not attenuate blunted alveolarization in a hyperoxia-based mouse model of bronchopulmonary dysplasia[J]. Pediatr Res, 2017, 81(5):795-805.
[34]
Tatler AL, Barnes J, Habgood A, et al. Caffeine inhibits TGFβ activation in epithelial cells, interrupts fibroblast responses to TGFβ, and reduces established fbrosis in ex vivo precision-cut lung slices[J]. Thorax, 2016, 71(6):565-567.
Endesfelder S, Zaak I, Weichelt U, et al. Caffeine protects neuronal cells against injury caused by hyperoxia in the immature brain[J]. Free Radic Biol Med, 2014, 67:221-234.
[37]
Tiwari KK, Chu C, Couroucli X, et al. Differential concentration-specific effects of caffeine on cell viability, oxidative stress, and cell cycle in pulmonary oxygen toxicity in vitro[J]. Biochem Biophys Res Commun, 2014, 450(4):1345-1350.
[38]
Choo-Wing R, Syed MA, Harijith A, et al. Hyperoxia and interferon-γ-induced injury in developing lungs occur via cyclooxygenase-2 and the endoplasmic reticulum stressdependent pathway[J]. Am J Respir Cell Mol Biol, 2013, 48(6):749-757.
[39]
Galán M, Kassan M, Kadowitz PJ, et al. Mechanism of endoplasmic reticulum stress-induced vascular endothelial dysfunction[J]. Biochim Biophys Acta, 2014, 1843(6):1063-1075.
[40]
Teng RJ, Jing X, Michalkiewicz T, et al. Attenuation of endoplasmic reticulum stress by caffeine ameliorates hyperoxiainduced lung injury[J]. Am J Physiol Lung Cell Mol Physiol, 2017, 312(5):L586-L598.
[41]
Hosoi T, Toyoda K, Nakatsu K, et al. Caffeine attenuated ER stress-induced leptin resistance in neurons[J]. Neurosci Lett, 2014, 569:23-26.
[42]
Ullah F, Ali T, Ullah N, et al. Caffeine prevents d-galactoseinduced cognitive defcits, oxidative stress, neuroinflammation and neurodegeneration in the adult rat brain[J]. Neurochem Int, 2015, 90:114-124.
[43]
Stefannie E, Ulrike W. Neuroprotection by caffeine in hyperoxia-induced neonatal brain injury[J]. Int J Mol Sci, 2017, 18(1):E187.
Saarenpää HK, Tikanmäki M, Sipola-Leppänen M, et al. Lung function in very low birth weight adults[J]. Pediatrics, 2015, 136(4):642-650.
[46]
Segerer FJ, Speer CP. Lung function in childhood and adolescence:influence of prematurity and bronchopulmonary dysplasia[J]. Z Geburtshilfe Neonatol, 2016, 220(4):147-154.
[47]
Landry JS, Tremblay GM, Li PZ, et al. Lung function and bronchial hyperresponsiveness in adults born prematurely. a cohort study[J]. Ann Am Thorac Soc, 2016, 13(1):17-24.
[48]
Kraaijenga JV, Hutten GJ, de Jongh FH, et al. The effect of caffeine on diaphragmatic activity and tidal volume in preterm infants[J]. J Pediatr, 2015, 167(1):70-75.
[49]
Kassim Z, Greenough A, Rafferty GF. Effect of caffeine on respiratory muscle strength and lung function in prematurely born, ventilated infants[J]. Eur J Pediatr, 2009, 168(12):1491-1495.
Dobson NR, Patel RM. The role of caffeine in noninvasive respiratory support[J]. Clin Perinatol, 2016, 43(4):773-782.
[52]
Katheria AC, Sauberan JB, Akotia D, et al. A pilot randomized controlled trial of early versus routine caffeine in extremely premature infants[J]. Am J Perinatol, 2015, 32(9):879-886.
Gupte AS, Gupta D, Ravichandran S, et al. Effect of early caffeine on neurodevelopmental outcome of very low-birth weight newborns[J]. J Matern Fetal Neonatal Med, 2016, 29(8):1233-1237.
[55]
Vesoulis ZA, McPherson C, Neil JJ, et al. Early high-dose caffeine increases seizure burden in extremely preterm neonates:a preliminary study[J]. J Caffeine Res, 2016, 6(3):101-107.
[56]
Yu T, Balch AH, Ward RM, et al. Incorporating pharmacodynamic considerations into caffeine therapeutic drug monitoring in preterm neonates[J]. BMC Pharmacol Toxicol, 2016, 17(1):22.
